Ortho-Clinical Diagnostics, Inc. VITROS Immunodiagnostic Products SARS-CoV-2 Antigen Reagent- In Vitro Diagnostic. The VITROS Immunodiagnostic Products SARS-CoV-2 Antigen Reagent Pack when used in combination with the VITROS Immunodiagnostic Products SARS-CoV-2 Antigen Calibrator is a chemiluminescent immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens in nasopharyngeal (NP) specimens. . For emergency authorization use only (EAU). Intended for Use in the United States Product Code: 6 Recall

Check Your Product

According to the U.S. Food and Drug Administration (FDA)

Reason for Recall

As stated by FDA

VITROS Immunodiagnostic Products SARS-CoV-2 Antigen False Reactive Results Associated When Using Remel M4RT Viral Transport Media

Recommended Action

Per FDA guidance

Ortho Clinical issued Urgent Product Correction Notification letter on 12 February 2021 (CL2021-064) stated reason , health risk and action to take: Ortho is collaborating with the manufacturer of Remel M4RT VTM to identify the root cause of the issue. " Ortho no longer recommends use of Remel M4RT VTM with the VITROS SARS-CoV-2 Antigen assay. " The VITROS SARS-CoV-2 Antigen Instructions for Use has been updated to remove Remel M4RT VTM from the Intended Use and to also add WHO formulation, Bartels FlexTrans and saline. The revised assay IFU is located on our website: https://www.orthoclinicaldiagnostics.com. Our website is the official source of information for all VITROS Products. Refer to the Revision History section included at the end of each IFU for a comprehensive list of changes. Technical changes in each IFU are marked by a change bar (|) to the left of the edited text. Discontinue use of Remel M4RT VTM and transition to an alternate media. " As your facility transitions to an alternate transport media, Ortho advises that your facility confirm the performance of each new lot of Remel M4RT VTM by doing the following: o Test each lot of Remel M4RT VTM with no specimen added, with and without the addition of extraction buffer. Suitable lots of Remel M4RT VTM will produce S/C values consistent with the values observed for the VITROS SARS-CoV-2 Antigen Control 1. o If possible, confirm the first 5 samples that produce reactive results on the VITROS SARS-CoV-2 Antigen assay using polymerase chain reaction (PCR) methodology, for each new lot of Remel M4RT VTM. " Post this notification by each system that processes the VITROS SARS-CoV-2 Antigen assay. " Complete the enclosed Confirmation of Receipt form no later than February 22, 2021. " Please forward this notification if the product was distributed outside of your facility.